Clinical trial
Arsenic Trioxide in Treating Patients With Multiple Myeloma
NCT00017433 · CTI BioPharma, Industry · Terminated
Key facts
| NCT number | NCT00017433 |
|---|---|
| Title | Arsenic Trioxide in Treating Patients With Multiple Myeloma |
| Official title | Phase II Study of Arsenic Trioxide in Patients With Multiple Myeloma |
| Lead sponsor | CTI BioPharma, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | arsenic trioxide |
| Start date | Jan 1, 2001 |
| Primary completion | Jan 1, 2005 |
| Completion | Jan 1, 2005 |
| First posted | Jan 8, 2004 |
| Last update posted | Oct 6, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: